Valuation: Cognetivity Neurosciences Ltd.

Market Cap 11.99L 8L 7L 7L 6L 8.11Cr 12.22L 82.08L 32.19L 3.98Cr 31.84L 31.14L 14Cr P/E 2022
-2.9x
P/E 2023 -2.8x
Enterprise Value 2L 2L 2L 1L 1L 1.66Cr 2L 16.79L 7L 81.51L 7L 6L 2.81Cr EV / Sales 2022
-
EV / Sales 2023 43,79,22,999x
Free-Float
85.56%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 45 01/04/2013
Compliance Officer 67 21/12/2017
Director TitleAgeSince
Director/Board Member 45 01/01/2017
Director/Board Member 67 21/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-33.33% - - 93
+3.52%+2.50%-28.66%-5.72% 3.2TCr
-2.08%-7.54%-38.54%+197.51% 1.44TCr
+1.42%-2.52%-20.49%+73.05% 569.91Cr
-2.10%-3.50% - - 225.61Cr
+3.92%+3.18%+62.70%-36.39% 212.3Cr
-0.31%-15.60% - - 183.06Cr
-1.41%-2.31%-30.87% - 109.11Cr
-2.81%-6.14%+47.16%+105.51% 92Cr
-0.94%+0.78%-33.39%+252.82% 82Cr
Average -0.08%-3.72%-6.01%+97.80% 679.28Cr
Weighted average by Cap. +1.45%-3.17%-25.83%+59.14%

Financials

2022 2023
Net sales - 0.05 0.03 0.03 0.03 0.02 3.07 0.05 0.31 0.12 1.51 0.12 0.12 5.21
Net income -1.31Cr -92.85L -81.44L -75.43L -69.4L -89Cr -1.34Cr -8.99Cr -3.53Cr -44Cr -3.49Cr -3.41Cr -150.72Cr -74.34L -52.58L -46.12L -42.71L -39.3L -50Cr -75.78L -5.09Cr -2Cr -25Cr -1.97Cr -1.93Cr -85Cr
Net Debt -82.43T -58.3T -51.14T -47.36T -43.58T -55.81L -84.03T -6L -2L -27.4L -2L -2L -94.64L -10L -7L -6L -5L -5L -6.45Cr -10L -65.29L -25.61L -3.17Cr -25.32L -24.77L -11Cr
Logo Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments and other neurological conditions. The Company’s CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. It is also focused on developing the ICA for home use, for the remote monitoring of patient’s progress under treatment regimens and for general home healthcare check-ups. CognICA is available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East. Its subsidiaries include Cognetivity Ltd. and Cognetivity FZ-LLC.
Employees
-